The litigation centers on claims that ADMA Biologics violated sections 10(b) and 20(a) of the Securities Exchange Act of 1934. According to the complaint, the company employed channel stuffing to artificially inflate revenue figures while failing to maintain necessary internal controls. These practices allegedly rendered public statements issued throughout the class period materially misleading. Shareholders seeking to participate in the potential recovery must contact the firm by August 10, 2026. As the class has not yet been certified, investors remain absent members unless they take affirmative steps to join the action. Brian Schall of the Los Angeles-based firm is managing inquiries regarding legal rights and potential compensation for affected parties.
Schall Law Firm Targets ADMA Biologics in Securities Fraud Class Action
Investors who purchased ADMA Biologics, Inc. securities between August 9, 2024, and March 25, 2026, are being urged to join a class action lawsuit. The Schall Law Firm alleges the company misled shareholders through undisclosed related-party transactions and revenue manipulation, causing significant financial damages once the truth surfaced.
Comments (0)
No comments yet. Be the first!